Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that include a psilocin mucate salt or conjugate, as well as methods for their production and use in treating conditions that can be addressed with psilocin. Both companies are focused on developing innovative treatments for diseases with significant unmet medical needs.
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) will assign the intellectual property rights for its second patent on Conjugated Psilocin™ to Alera Pharma, its wholly owned subsidiary. Mr. Rick Goulburn, CEO of Alera Pharma, Inc., commented, “We are thrilled to receive this second patent allowance for Conjugated Psilocin™, which recognizes the unique properties of this psilocin analogue. We are moving forward with our fundraising efforts to develop Conjugated Psilocin™ as a potential treatment for Chronic Cluster Headache.”
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences, added, “As we continue to gather data on Conjugated Psilocin™, we are increasingly confident that this new chemical entity could lead to a wide range of therapeutic applications. Conjugated Psilocin™ offers a stable form of psilocin, the active metabolite of psilocybin, with superior pharmacokinetics, including rapid and reproducible absorption. These advantages may make it a more effective option than psilocybin itself.”
About Conjugated Psilocin™
Conjugated Psilocin™ is a patented, novel, and stable oral analogue of psilocin, the active metabolite of psilocybin. Psilocybin is a psychedelic compound with recognized therapeutic potential in various neurological conditions. However, psilocybin is converted to psilocin, which suffers from poor bioavailability and pharmacokinetics. Psilocin is also highly unstable, making it difficult to develop as a pharmaceutical treatment. Conjugated Psilocin™ overcomes these challenges by offering a stable, highly bioavailable formulation that could be developed as a prescription medicine for several neurological disorders.
About Lobe Sciences Ltd.
Lobe Sciences, Ltd. is a commercial-stage biotechnology company focused on developing innovative therapies for unmet medical needs. Through its subsidiaries, Alera Pharma, Inc. and Altemia, Inc., Lobe Sciences is advancing patented drug candidates to treat chronic cluster headaches (Alera) and developing medical foods to address deficiencies in sickle cell disease (Altemia). Lobe Sciences provides administrative and operational support to its subsidiaries, including accounting, finance, and general services.
About Alera Pharma, Inc.
Alera Pharma, Inc., a wholly owned subsidiary of Lobe Sciences, is dedicated to developing and commercializing pharmaceutical products that address significant unmet medical needs. With a focus on neurological disorders, Alera Pharma is committed to improving patient outcomes through innovative research and drug development.
